Product development issues for PEGylated proteins. - Wikidata - wikimedia - TriplyDB

Product development issues for PEGylated proteins.

Product development issues for PEGylated proteins.

http://www.wikidata.org/entity/Q37790702

about

PEG-like nanoprobes: multimodal, pharmacokinetically and optically tunable nanomaterials.Nasal commensal Staphylococcus epidermidis counteracts influenza virus.Site-specific PEGylation of therapeutic proteins via optimization of both accessible reactive amino acid residues and PEG derivatives.Targeted interception of signaling reactive oxygen species in the vascular endothelium Novel drug discovery strategies for gout.The immunogenicity of polyethylene glycol: facts and fiction.Unnatural amino acid incorporation in E. coli: current and future applications in the design of therapeutic proteins PEGylation and its impact on the design of new protein-based medicines.Optimization of random PEGylation reactions by means of high throughput screening.Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents.PEG chain length impacts yield of solid-phase protein PEGylation and efficiency of PEGylated protein separation by ion-exchange chromatography: insights of mechanistic models.

P2860

Q35159784-0FD94BF3-8252-4D14-B874-19B10BAC1133 Q37010479-B7245783-859F-4982-A8BD-C721EABB15B4 Q38020590-E591762B-8470-4D60-90D2-42F8E0CACED0 Q38029695-8D31BBAE-796F-4D7B-8A31-1F5DF4C3C1BF Q38066561-10487BB1-8757-4544-B52D-D9AB8BDB0D51 Q38106847-63E38329-0F4F-4E0C-BABD-75946E986F8D Q38208848-039A1B5E-1312-4973-873C-43AEA6B4C13E Q38269324-F6913422-F5F6-45F2-913C-18E2DE539F76 Q45178029-B98678BC-BA9E-40C1-AE98-8F90C636B912 Q45717861-6453FD1F-86E4-484E-AAB1-F518AEB8C5FA Q46355326-1598B6DB-BD9C-4356-A1F8-1476AA9881C9

P2860

Product development issues for PEGylated proteins.

http://www.wikidata.org/entity/Q37790702

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 21 September 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Product development issues for PEGylated proteins.

@en

Product development issues for PEGylated proteins.

@nl

type

label

Product development issues for PEGylated proteins.

@en

Product development issues for PEGylated proteins.

@nl

prefLabel

Product development issues for PEGylated proteins.

@en

Product development issues for PEGylated proteins.

@nl

P1433

Q37790702-89C3017A-F6F6-4135-941B-FEC098CA4D93

P1476

Q37790702-080C53FF-D526-44F4-B611-F7C5B4543C3E

P2093

Q37790702-1F168A69-DEB7-41D2-911E-7E33B6EFA3F2

Q37790702-7111C48E-AEEA-4BB6-A9EA-195BC9732DFF

Q37790702-B4C2C528-1521-433A-8FBB-73CB126C731E

P2860

Q37790702-023658F8-42C6-4E47-9501-2FCDE7D92D54

Q37790702-05A16C36-A8AF-43C7-9DA2-76373978DB30

Q37790702-05B95B79-2D31-4525-9DDE-F998A9CED801

Q37790702-077BF9EA-874F-4698-93CC-29D00C92CDB6

Q37790702-08105199-ECF7-46D0-B47C-3CA910EA9B19

Q37790702-09567A84-ACB7-4912-B519-352EFBD009C9

Q37790702-0BB4DFFB-B575-4C41-8629-02CE4EBC5B8A

Q37790702-0CBB40B7-5E7F-489A-A064-DB6F7A8808D3

Q37790702-0CE475C9-3FA9-43E6-8831-C4F1EDE17501

Q37790702-0FFDE920-0DD6-455B-8197-26269B74616C

P304

Q37790702-9FAD7F21-68F1-4583-A8F7-044ECE788A6E

P31

Q37790702-5553245E-7399-4546-85BD-83CA65E7D952

P356

Q37790702-DFD0A849-3C1C-472F-BE73-65D021004C87

P433

Q37790702-CCE207BD-F3BB-4797-94C2-603E894040F5

P478

Q37790702-A7E79B4C-02DC-4944-BCE3-2F6E63CCEF82

P577

Q37790702-E07A4371-D87B-465A-B2DC-C1CA944DA325

P5875

Q37790702-2A1ED32E-BFD4-4EA0-B642-A4CBD66E000E

P698

Q37790702-2EC6ABDB-341A-456B-92C1-E04005EF05A3

P356

10837450.2010.513990

P1433

Pharmaceutical Development and Technology

P1476

Product development issues for PEGylated proteins.

@en

P2093

Brian M Murphy

http://www.w3.org/2001/XMLSchema#string

Mark Cornell Manning

http://www.w3.org/2001/XMLSchema#string

Robert W Payne

http://www.w3.org/2001/XMLSchema#string

P2860

Tissue sulfhydryl groups

Peptide and protein PEGylation: a review of problems and solutions

Pegaspargase: a review of clinical studies

Size-exclusion reaction chromatography (SERC): a new technique for protein PEGylation

Microbial degradation of polyethers

PEG-uricase in the management of treatment-resistant gout and hyperuricemia

Advances in PEGylation of important biotech molecules: delivery aspects

PEGylation, successful approach to drug delivery

Structural characterization of PEGylated rHuG-CSF and location of PEG attachment sites.

Site-specific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase.

P304

423-440

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/10837450.2010.513990

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2010-09-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46392469

http://www.w3.org/2001/XMLSchema#string

P698

20858059

http://www.w3.org/2001/XMLSchema#string